Istanbul, Turkey

Kemal Baysal

This inventor holds 1 USPTO granted patent. Top assignees: Istanbul Teknik Üniversitesi, Koç Üniversitesi. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kemal Baysal. Retrieved from https://idiyas.com/inventor/kemal-baysal-iufta1bl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kemal Baysal: Microfluidic Innovation in 3D Cell Culture

Introduction

Kemal Baysal is an inventor based in Istanbul, Türkiye. His patent work focuses on a three-dimensional microfluidic platform designed for cell culture and the study of angiogenesis.

Latest Patents

Baysal is associated with 1 patent: “Microfluidic Platform for Enabling Cell Culturing in a Three Dimensional Microenvironment.” The invention describes a microfluidic cartridge with a raised side area and a lower central area. It supports three-dimensional cell culture, tumor spheroid formation, and observation of angiogenesis. The platform can also be used to measure endothelial-cell responses to angiogenic and antiangiogenic small molecules, drugs, and protein therapeutics.

Career Highlights

Baysal’s listed institutional affiliations include Koç University and Istanbul Technical University. His patent reflects work at the intersection of microfluidics, cell culture, and biomedical research.

Collaborations

His listed coworkers include Alper Kiraz and Ahmet C. Erten.

Conclusion

Kemal Baysal’s patented microfluidic platform provides a research tool for cultivating cells in a three-dimensional environment and evaluating angiogenesis and treatment responses.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…